Ameriprise
URGN icon

Ameriprise’s UroGen Pharma URGN Stock Holding History

Ameriprise’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
31,668
+1,502
+5% +$40.7K ﹤0.01% 3335
2026
Q1 		$542K Sell
30,166
-105,853
-78% -$2.12M ﹤0.01% 3558
2025
Q4 		$3.19M Buy
136,019
+105,535
+346% +$2.29M ﹤0.01% 2749
2025
Q3 		$608K Sell
30,484
-396
-1% -$7.11K ﹤0.01% 3560
2025
Q2 		$423K Sell
30,880
-2,878
-9% -$27.6K ﹤0.01% 3587
2025
Q1 		$373K Sell
33,758
-15,395
-31% -$164K ﹤0.01% 3604
2024
Q4 		$523K Buy
49,153
+4,188
+9% +$50.1K ﹤0.01% 3512
2024
Q3 		$571K Sell
44,965
-110
-0.2% -$1.63K ﹤0.01% 3437
2024
Q2 		$756K Sell
45,075
-25,877
-36% -$368K ﹤0.01% 3280
2024
Q1 		$1.06M Sell
70,952
-2,009
-3% -$32.8K ﹤0.01% 3137
2023
Q4 		$1.09M Sell
72,961
-13,148
-15% -$171K ﹤0.01% 3146
2023
Q3 		$1.21M Buy
86,109
+1,069
+1% +$17.2K ﹤0.01% 3057
2023
Q2 		$880K Buy
85,040
+4,033
+5% +$44.5K ﹤0.01% 3227
2023
Q1 		$749K Hold
81,007
– – ﹤0.01% 3276
2022
Q4 		$718K Sell
81,007
-1,042
-1% -$9.87K ﹤0.01% 3270
2022
Q3 		$682K Buy
+82,049
New +$679K ﹤0.01% 3280

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ameriprise's URGN Position: Q2 2026 in Review

Ameriprise increased its UroGen Pharma (URGN) stake by 5% in Q2 2026, buying an estimated $40.7K and bringing the position to 31,668 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3335.

Ameriprise first reported a position in URGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $3.19M in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Ameriprise held 31,668 shares of UroGen Pharma worth $1.17M as of Q2 2026.
  • Ameriprise bought 1,502 UroGen Pharma shares in Q2 2026, an estimated $40.7K.
  • UroGen Pharma made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3335 holding.
  • Ameriprise first reported a position in UroGen Pharma in Q3 2022 and has held it in 16 quarters since.
  • Ameriprise's UroGen Pharma position peaked at $3.19M in Q4 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.